Abstract
The question of whether screen detection confers an additional survival benefit in breast cancer is unclear and subject to several biases. Our aim was to examine the role of the diagnostic method (screen-detected, symptom-detected, and true interval cancers) and the clinical-pathological features in relapse-free survival and overall survival in breast cancer patients. We included 228 invasive breast cancers diagnosed in Barcelona from 1996 to 2008 among women aged 50-69 years. Ninety-seven patients were screen detected within the screening, 34 truly arose between 2-year screening mammograms (true interval cancers), and 97 were symptom detected outside the screening. The clinical-pathological features at diagnosis were compared. The overall and disease-free survival probabilities were computed using the Kaplan-Meier method. Cox proportional hazard models were applied, with adjustment by clinical-pathological variables. At diagnosis, symptom-detected and true interval cancers were in more advanced stages and were less differentiated. The highest proportion of triple-negative cancers was detected among true interval cancers (P=0.002). At 5 years of follow-up, the disease-free survival rates for screen-detected, true interval, and ...Continue Reading
Citations
Jan 1, 2014·Medicina clínica·Montse Puig-VivesRafael Marcos-Gragera
Dec 15, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Masaaki KawaiNoriaki Ohuchi
Sep 18, 2015·Cancer Causes & Control : CCC·Adana A M LlanosKitaw Demissie
Mar 21, 2015·AJR. American Journal of Roentgenology·Jessica M EngelAdedayo A Onitilo
Oct 22, 2014·PloS One·Jordi BlanchUNKNOWN INCA Study Group
Aug 3, 2014·BMC Cancer·Gemma Renart-VicensRafael Marcos-Gragera
Sep 13, 2016·International Journal of Cancer. Journal International Du Cancer·Fredrik StrandKamila Czene
Oct 8, 2016·Breast Cancer Research : BCR·Fredrik StrandKamila Czene
Dec 21, 2016·Cancer Causes & Control : CCC·Solenne Delacour-BillonFlorence Molinié
Jun 27, 2017·NPJ Breast Cancer·Nehmat Houssami, Kylie Hunter
Feb 18, 2017·Cancer Medicine·Elisabetta RapitiChristine Bouchardy
Apr 8, 2018·BMC Cancer·Gautier DefossezPierre Ingrand
Jan 24, 2019·Breast Cancer Research and Treatment·Melissa PilewskieMaxine S Jochelson
Dec 25, 2013·British Journal of Cancer·A DibdenS W Duffy
Jul 3, 2019·Breast Cancer Research and Treatment·Samantha PuvanesarajahMia M Gaudet
Jul 22, 2014·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Shu-Lin ChuangHsiu-Hsi Chen
Dec 14, 2018·Breast Cancer Research : BCR·Tuong L NguyenJohn L Hopper
Dec 15, 2018·Journal of Evaluation in Clinical Practice·Urko AguirreUNKNOWN CAMISS Study Group
Aug 24, 2016·The Breast Journal·Martha E GoodrichUNKNOWN Breast Cancer Surveillance Consortium
Jun 18, 2018·Journal of Cancer Research and Clinical Oncology·Claire M B HollowayPatti A Groome
Jun 19, 2020·Cancers·M Ángeles López-GarcíaJosé Palacios
Dec 19, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Federico RojoXavier Castells
Jul 23, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Mylove MortelRichard B Warnecke
Jan 10, 2021·Breast Cancer Research and Treatment·Johanna AlankoJorma Isola
Mar 18, 2021·European Journal of Radiology·Maeve MulloolyOrla Healy